BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

NEWS: BDSI Completes Acquisition of ELYXYB Learn More >
PRODUCT EXPANSION

Continuing Efforts

BDSI is committed to pursuing clinical developments that bring new, meaningful therapies to patients living with serious and debilitating conditions.

Scroll down to see some of our latest initiatives.

Focused on launching pediatric clinical studies on ELYXYB™ (celecoxib oral solution) for the treatment of acute migraine

Exploring the potential of a new indication for ELYXYB for the treatment of acute pain

Further evaluating the expansion of ELYXYB into Canada

ELYXYB INDICATION AND USAGE

ELYXYB is indicated in adults for the acute treatment of migraine with or without aura.

Limitations of Use: ELYXYB is not indicated for the preventive treatment of migraine.

ELYXYB IMPORTANT SAFETY INFORMATION

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, 1-800-FDA-1088. Report an Adverse Event

Recent BDSI News

November 3, 2021

Total Net Revenue of $41.1 Million , an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07 , EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potential

Read more
October 21, 2021

RALEIGH, N.C. , Oct. 21, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the appointment of John Golubieski as Chief Financial

Read more
October 20, 2021

RALEIGH, N.C. , Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it will report its third quarter 2021 financial results before the open of

Read more
More news

Upcoming Events

There are no events to display

Stay Connected

Stay up to date on the latest news

Get started now
November 29, 2021BDSI $2.82/ - -3.09%
Data provided by Nasdaq. Minimum 15 minutes delayed.